Αρχική World News FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer World News FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer Από Ogkologos - 19 Σεπτεμβρίου, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Gym Offers Free Membership & Support To Those Struggling With Addiction 25 Οκτωβρίου, 2021 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... 17 Μαΐου, 2024 Reducing Health Care Disparities Through Cancer Clinical Trials 30 Νοεμβρίου, 2020 Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs 25 Ιουνίου, 2020 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+... Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... Study Advances Fertility Preservation Approach for Male Cancer Survivors Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive